Results 61 to 70 of about 232,812 (303)

Chromosomal Abnormalities, Drug Sensitivity and Resistance in Hematological Malignancies: A Comprehensive Overview by the Francophone Group of Hematological Cytogenetics (GFCH)

American Journal of Hematology, EarlyView.
ABSTRACT Chromosomal abnormalities have a major clinical impact on hematological malignancies, particularly with regard to treatment strategies. To preserve and consolidate fundamental knowledge in this rapidly evolving field, the Francophone Group of Hematological Cytogenetics (Groupe Francophone de Cytogénétique Hématologique, GFCH) conducted a ...
Florence Nguyen‐Khac, Audrey Bidet, Elise Chapiro, Nathalie Douet‐Guilbert, Jean‐Baptiste Gaillard, Nada Assaf, Nathalie Auger, Hend Chaker, Jasmine Chauzeix, Inge Govaerts, Hippolyte Guérineau, Christine Lefebvre, Pauline Roynard, Hélène Guermouche, Lucienne Michaux, Marie‐Bérengère Troadec, Lauren Véronèse   +16 more
wiley   +1 more source

S300: HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE REAL-LIFE MULTIPLE MYELOMA PATIENTS TREATED WITH BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD)

HemaSphere, 2022
M. D’Agostino, S. Bringhen, R. Ria, F. Ciceri, A. P. Falcone, M. Michieli, M. Grasso, F. Pane, M. Quaresima, F. Cattel, M. Mirabile, F. Fioritoni, M. T. Petrucci, V. Cotugno, A. Capra, S. Pezzatti, M. L. Mosca Siez, M. Cantonetti, G. Margiotta Casaluci, P. Bertazzoni, R. Floris, M. Offidani, G. Pietrantuono, A. Evangelista, M. Boccadoro, A. Larocca   +25 more
doaj   +1 more source

NF-κB signaling and its relevance to the treatment of mantle cell lymphoma

Journal of Hematology & Oncology, 2018
Mantle cell lymphoma is an aggressive subtype of non-Hodgkin B cell lymphoma that is characterized by a poor prognosis determined by Ki67 and Mantle Cell International Prognostic Index scores, but it is becoming increasingly treatable.
Swathi Balaji, Makhdum Ahmed, Elizabeth Lorence, Fangfang Yan, Krystle Nomie, Michael Wang   +5 more
doaj   +1 more source

Myeloma Nursing Competency Framework

, 2015
The Myeloma Nursing Competency Framework has been developed to enable nurses at all levels to demonstrate that they are equipped with the knowledge, skills, behaviours and competencies required to deliver the highest quality of treatment, management and ...
Perkins, Sue, Lobban, Lois, Blair, Susan, Behrens, Judith, Cruickshank, Susanne, Smith, Alastair, Deppe, Sophie, Low, Eric, Tonkin, Joanne   +8 more
core  

Second malignancies after multiple myeloma: from 1960s to 2010s. [PDF]

, 2012
To access publisher's full text version of this article. Please click on the hyperlink in Additional Links field.Based on small numbers, recent reports from 3 randomized trials have consistently demonstrated more hematologic malignancies in patients ...
Kristinsson, Sigurdur Y., Turesson, I, Thomas, A, Mailankody, Sham, Korde, Neha, Kristinsson, Sigurdur Y, Turesson, Ingemar, Mailankody, S, Landgren, Ola, Korde, N, Thomas, Anish, Lund University., Landgren, Carl, Turesson, Ingemar,, Kristinsson, SY, Landgren, O   +15 more
core   +1 more source

Cancer Incidence Among Swedish Seafarers Between 1985 and 2020

American Journal of Industrial Medicine, EarlyView.
ABSTRACT Background Several studies from different countries have shown that merchant seafarers have an increased cancer risk compared to the general population. The aim of this study was to provide updated information on cancer incidence in a cohort of Swedish seafarers.
Maria Wallin, Helena P. Eriksson, Karl Forsell, Eva Andersson   +3 more
wiley   +1 more source

Development of multiple myeloma in a patient with chronic hepatitis C: A case report and review of the literature [PDF]

, 2006
An association between chronic hepatitis C virus (HCV) infection and essential mixed cryoglobulinaemia and non-Hodgkin lymphoma (NHL) has been suggested. However, a causative role of HCV in these conditions has not been established.
Lakatos, Péter László, Horányi, Margit, Abonyi, Margit E., Fischer, Simon, Fekete, Sándor   +4 more
core   +1 more source

P946: A PHASE I/II SINGLE ARM STUDY OF BELANTAMAB MAFODOTIN, CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA: AMARC 19-02 BELACARD STUDY.

HemaSphere, 2022
M. Lasica, A. Spencer, P. Campbell, C. Wallington-Gates, N. Wong Doo, W. Janowski, G. McCaughan, A. Puliyayil, F. Yuen, K. Le, J. Reynolds, H. Quach   +11 more
doaj   +1 more source

Tocilizumab prophylaxis for patients with multiple myeloma treated with bispecific antibodies

Blood Advances
: Bispecific antibodies for treatment for multiple myeloma are highly effective but commonly cause cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS).
Andrew Kowalski, Jill Lykon, Benjamin Diamond, David Coffey, Marcella Kaddoura, Francesco Maura, James Hoffman, Abhishek Pandey, Dickran Kazandjian, Ola Landgren   +9 more
doaj   +1 more source

Axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma patients in complete metabolic response

Haematologica, 2022
Andrew P. Jallouk, Sushanth Gouni, Jason Westin, Lei Feng, Haleigh Mistry, Raphael E. Steiner, Jinsu James, Mansoor Noorani, Sandra Horowitz, Nahum Puebla-Osorio, Luis E. Fayad, Swaminathan P. Iyer, Misha Hawkins, Christopher R. Flowers, Sairah Ahmed, Loretta J. Nastoupil, Partow Kebriaei, Elizabeth J. Shpall, Sattva S. Neelapu, Yago Nieto, Paolo Strati   +20 more
doaj   +1 more source